

PRESS RELEASE

Gradientech distributor a.d.a. wins tenders for QuickMIC® at two important Italian hospitals

Uppsala, Sweden, June 19, 2025. The diagnostics company Gradientech and its Italian distributor a.d.a. SRL, today announce the successful awarding of two direct tenders for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) directly from blood culture samples.

The Italian hospitals, Azienda USL Valle d'Aosta in Aosta and P.O. Michele e Pietro Ferrero in Alba have, following direct tender procedures, selected QuickMIC® for integration into their clinical workflow for AST of sepsis samples. QuickMIC systems have already been installed at both hospitals and are now in the process of being implemented in clinical routine, marking a significant milestone in Gradientech's European growth strategy.

"This strategic win marks a major step in expanding the footprint of QuickMIC in Italy and highlights the growing recognition of the clinical and operational value of rapid AST in combating infectious diseases and antimicrobial resistance. QuickMIC delivers precise and accurate AST results in just 2–4 hours, which is essential for confirming and adjusting antimicrobial treatment in a timely manner," say Andrea Grillo, Managing Director, and Pietro Lombardi, Scientific Director of a.d.a. SRL, Gradientech's exclusive distributor in Italy.

"Winning these tenders is a strong endorsement of our technology and our mission to accelerate access to life-saving sepsis diagnostics. It also shows that we can meet the needs of hospitals and laboratories of varying sizes with the modular setup of QuickMIC," says Sara Thorslund, CEO and co-founder of Gradientech. "The Italian market is proving to be at the forefront of adopting rapid AST diagnostics to improve patient outcomes — progress that is undoubtedly driven by the excellent work of a.d.a. and their experienced team in Italy."

The ultra-rapid and precise antibiotic susceptibility testing results of QuickMIC® contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Its modular design offers affordable scaling possibilities, making QuickMIC suitable for both small and large hospital laboratories. QuickMIC and its gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.

For further information, please contact:

Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.